In order to restore NK cell activity against HLA-I+ tumor cells, novel immunotherapies have been developed, based on the use of therapeutic monoclonal antibodies anti-pan-KIR2D (lirilumab) (https://www.innate-pharma.com/en/pipeline/lirilumab-first-class-anti-kir-mab-licensed-bristol-myers-squibb) and anti-NKG2A (monalizumab) (https://www.innate-pharma.com/en/pipeline/monalizumab-anti-nkg2a-mab-partnered-astrazeneca) mimicking “missing-self” response by disrupting the interaction between these ICs and their ligands. Here, KLRC1 is linked to neoplasm.